{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:19Z","timestamp":1790767279511,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:00:00Z","timestamp":1306108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.<\/jats:p>\n            <jats:p>At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2466-11-30","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T06:48:19Z","timestamp":1306219699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?"],"prefix":"10.1186","volume":"11","author":[{"given":"Jan K","family":"Hennigs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00f6rg","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Honecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"issue":"14","key":"264_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 2004, 351 (14): 1425-1436. 10.1056\/NEJMra040291.","journal-title":"N Engl J Med"},{"issue":"4","key":"264_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00000441-200104000-00009","volume":"321","author":"ED Michelakis","year":"2001","unstructured":"Michelakis ED, Weir EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci. 2001, 321 (4): 292-299. 10.1097\/00000441-200104000-00009.","journal-title":"Am J Med Sci"},{"key":"264_CR3","volume-title":"European Public Assessment Report (EPAR)","author":"EMEA","year":"2008","unstructured":"EMEA: Sprycel - Scientific Discussion. European Public Assessment Report (EPAR). 2008, (EMEA\/H\/C\/709)"},{"key":"264_CR4","volume-title":"Dasatinib - Pharmacogenomic Information: Indications and Usage","author":"FDA","year":"2010","unstructured":"FDA: Dasatinib - Pharmacogenomic Information: Indications and Usage. 2010"},{"issue":"6","key":"264_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","volume":"33","author":"W Rasheed","year":"2009","unstructured":"Rasheed W, Flaim B, Seymour JF: Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009, 33 (6): 861-864. 10.1016\/j.leukres.2008.09.026.","journal-title":"Leuk Res"},{"issue":"12","key":"264_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bmt.2008.415","volume":"43","author":"D Mattei","year":"2009","unstructured":"Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A: Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009, 43 (12): 967-968. 10.1038\/bmt.2008.415.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"264_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P: Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007, 176 (8): 814-818. 10.1164\/rccm.200705-715CR.","journal-title":"Am J Respir Crit Care Med"},{"issue":"25","key":"264_CR8","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007, 25 (25): 3908-3914. 10.1200\/JCO.2007.12.0329.","journal-title":"J Clin Oncol"},{"issue":"6","key":"264_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1183\/09031936.00139009","volume":"34","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009, 34 (6): 1219-1263.","journal-title":"Eur Respir J"},{"issue":"1 Suppl","key":"264_CR10","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009, 54 (1 Suppl): S43-54.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"264_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000112822","volume":"76","author":"P Guilpain","year":"2008","unstructured":"Guilpain P, Montani D, Damaj G, Achouh L, Lefr\u00e8re F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, et al: Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration. 2008, 76 (3): 295-302. 10.1159\/000112822.","journal-title":"Respiration"},{"issue":"6","key":"264_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1378\/chest.08-2006","volume":"135","author":"S Harch","year":"2009","unstructured":"Harch S, Whitford H, McLean C: Failure of medical therapy in pulmonary arterial hypertension. Is there an alternative diagnosis?. Chest. 2009, 135 (6): 1462-1469. 10.1378\/chest.08-2006.","journal-title":"Chest"},{"issue":"10","key":"264_CR13","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005, 115 (10): 2811-2821. 10.1172\/JCI24838.","journal-title":"J Clin Invest"},{"issue":"13","key":"264_CR14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMc051946","volume":"353","author":"HA Ghofrani","year":"2005","unstructured":"Ghofrani HA, Seeger W, Grimminger F: Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005, 353 (13): 1412-1413. 10.1056\/NEJMc051946.","journal-title":"N Engl J Med"},{"issue":"2","key":"264_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","volume":"145","author":"KC Patterson","year":"2006","unstructured":"Patterson KC, Weissmann A, Ahmadi T, Farber HW: Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006, 145 (2): 152-153.","journal-title":"Ann Intern Med"},{"issue":"8","key":"264_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/thx.2006.064097","volume":"61","author":"R Souza","year":"2006","unstructured":"Souza R, Sitbon O, Parent F, Simonneau G, Humbert M: Long term imatinib treatment in pulmonary arterial hypertension. Thorax. 2006, 61 (8): 736-","journal-title":"Thorax"},{"issue":"6","key":"264_CR17","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1378\/chest.07-1724","volume":"132","author":"DC Grinnan","year":"2007","unstructured":"Grinnan DC, Fairman P, Pinson J: Recurrence of severe pulmonary hypertension following the removal of a lung allograft. Chest. 2007, 132 (6): 2057-2058. 10.1378\/chest.07-1724. author reply 2058","journal-title":"Chest"},{"issue":"9","key":"264_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010, 182 (9): 1171-1177. 10.1164\/rccm.201001-0123OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"264_CR19","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007, 110 (12): 4055-4063. 10.1182\/blood-2007-07-102061.","journal-title":"Blood"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-11-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-11-30\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-11-30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-11-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:09:01Z","timestamp":1630505341000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-11-30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-11-30","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,23]]},"assertion":[{"value":"2 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"30"}}